Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
- Pharma Regulation Panel to Discuss Need for PI Japanese Data on Aug. 7
August 1, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan Panel Shelves Decision on Shionogi’s COVID Vaccine over Efficacy Data
August 1, 2023
- First Two Homegrown COVID-19 Jabs Up for MHLW Panel Review on July 31
July 31, 2023
- Japan Safety Panels Recognize 2nd Death Possibly Linked to COVID Vaccine
July 31, 2023
- Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
July 28, 2023
- Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
July 28, 2023
- Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
July 27, 2023
- Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing
July 27, 2023
- Chuikyo Divided Over Raising Premium Rates for Listed Products, Extending Evaluation Data
July 27, 2023
- Japan OKs FY2024 Budget Ceilings, 520 Billion Yen for Social Security Cost Rise
July 26, 2023
- MHLW Pharma Bureau Chief Eager to Do Everything on Regulation Panel’s Agenda
July 25, 2023
- Label Expansions for Jakavi, Soliris in Line for Approval
July 25, 2023
- Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
July 25, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…